New class of proteins allows breast cancer cells to evade tyrosine kinase inhibitors

August 13, 2012

Aberrant regulation of cell growth pathways is required for normal cells to become cancerous, and in many types of cancer, cell growth is driven by a group of enzymes known as receptor tyrosine kinases (RTKs). The RTK epidermal growth factor receptor (EGFR) is overexpressed in over 30% of breast cancers; however, drugs that target RTKs, known as tyrosine kinase inhibitors (TKIs) have not been effective in treating breast cancer. Researchers believe that the cancer cells escape TKIs by circumventing the RTKs and utilizing other enzymes that are not TKI-sensitive.

In the current issue of the , two groups identify a pair of related oncogenes, FAM83A and B, which allow to survive TKI treatment. Researchers led by Mina Bissell at the Lawrence Berkeley National Laboratory in Berkeley, CA performed a screen of human breast cancer cell lines to identify genes that make cancer cells resistant to EGFR TKIs.

Bissell and colleagues determined that increased expression of FAM83A increases proliferation and invasion, while decreased expression delays tumor growth in mice and renders cancer cells sensitive to TKIs.

At Case Western Reserve Medical School in Cleveland, OH, Mark Jackson and colleagues identified FAM83B as a gene that allows normal human mammary cells to become malignant. Further, expression of FAM83A and B in human tumors was correlated with decreased overall survival. Taken together, these studies identify two genes that may serve as novel therapeutic targets.

In a companion piece, Steven Grant of the Medical College of Virginia discusses the impact of this research on the development of strategies to overcome resistance to currently available TKIs.

Explore further: PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors

More information:
Identification of FAM83B as a novel intermediary in EGFR/RAS-mediated transformation, Journal of Clinical Investigation.
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice, Journal of Clinical Investigation.
FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators, Journal of Clinical Investigation.

Related Stories

Double whammy: RNAi enhances lung cancer therapy

March 20, 2012

Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors ...

Recommended for you

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

Is there a link between telomere length and cancer?

March 23, 2017

Telomeres are regions of repetitive DNA at the end of human chromosomes, which protect the end of the chromosome from damage. Whilst shorter telomeres are hypothesized biological markers of older age and have been linked ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.